Verona Pharma plc Verona Pharma Announces August 2020 Virtual Investor Conference Participation

 
TIDMVRP 
 
   LONDON and RALEIGH, N.C., Aug. 03, 2020 (GLOBE NEWSWIRE) -- Verona 
Pharma plc (AIM: VRP) (Nasdaq: VRNA) ("Verona Pharma"), a clinical-stage 
biopharmaceutical company focused on respiratory diseases, announces 
that David Zaccardelli, Chief Executive Officer and President, and Mark 
Hahn, Chief Financial Officer, will present a company overview at the 
following virtual investor conferences in August 2020: 
 
   BTIG Virtual Biotechnology Conference 
 
   Date: Monday, August 10 
 
   Time: 2:30 PM ET 
 
   Wedbush PacGrow Healthcare Virtual Conference 
 
   Date: Wednesday, August 12 
 
   Time: 11:30 AM ET 
 
   40th Annual Canaccord Genuity Growth Conference 
 
   Date: Thursday, August 13 
 
   Time: 4:30 PM ET 
 
   A live webcast of each event will be available on the Events and 
Presentations link on the Investors page of the Company's website, 
https://www.globenewswire.com/Tracker?data=snzsPRZZHzT83uiX6apAlyb2FOyEOl3vs5BTf8CwVxMQUuDeG_nDsLJ4cV4H7I08OSM4Kw2BUye3i8X7Pf1vvjNRJxraMTUDRaLlUb2yI1Y= 
www.veronapharma.com, and an audio replay will be available there for 30 
days. 
 
   About Verona Pharma 
 
   Verona Pharma is a clinical-stage biopharmaceutical company focused on 
developing and commercializing innovative therapies for the treatment of 
respiratory diseases with significant unmet medical needs. If 
successfully developed and approved, Verona Pharma's product candidate, 
ensifentrine, has the potential to be the first therapy for the 
treatment of respiratory diseases that combines bronchodilator and 
anti-inflammatory activities in one compound. Following a response from 
the U.S. FDA to Verona Pharma's End-of-Phase 2 briefing package, the 
Company plans to initiate its Phase 3 clinical program ENHANCE 
(Ensifentrine as a Novel inHAled Nebulized COPD thErapy) later in 2020 
for nebulized ensifentrine for COPD maintenance treatment. The Company 
raised gross proceeds of $200 million through a private placement in 
July 2020 and expects the funds to support its operations and Phase 3 
clinical program into 2023. Verona Pharma is currently in Phase 2 
development with two additional formulations of ensifentrine for the 
treatment of COPD: dry powder inhaler (DPI) and pressurized metered-dose 
inhaler. Ensifentrine also has potential applications in cystic fibrosis, 
asthma and other respiratory diseases. For more information, please 
visit www.veronapharma.com. 
 
 
 
 
 
  Verona Pharma plc                                       Tel: +44 (0)20 3283 4200 
  Victoria Stewart, Director of Communications            info@veronapharma.com 
 
  N+1 Singer                                              Tel: +44 (0)20 3283 4200 
   (Nominated Adviser and UK Broker) 
  Aubrey Powell / George Tzimas / Iqra Amin (Corporate 
   Finance) 
  Tom Salvesen (Corporate Broking) 
 
  Optimum Strategic Communications                        Tel: +44 (0)20 950 9144 
   (European Media and Investor Enquiries)                 verona@optimumcomms.com 
  Mary Clark / Eva Haas / Shabnam Bashir 
 
  Argot Partners                                          Tel: +1 212-600-1902 
   (US Investor Enquiries)                                 verona@argotpartners.com 
  Kimberly Minarovich / Michael Barron

(END) Dow Jones Newswires

August 03, 2020 02:00 ET (06:00 GMT)

Verona Pharma (LSE:VRP)
Historical Stock Chart
From Jun 2024 to Jul 2024